Patents Exclusive patents across multiple key healthcare applications
In both dogs and mice, rapamycin therapy improves cardiac function and can potentially treat hepatic glycogen storage disease.[4, 24, 25, 3335] Inhibition of mTOR also results in decreased smooth-muscle cell migration and proliferation within coronary arteries, with rapamycin-coated coronary stents significantly reducing arterial stenosis following stent placement.[36] Still, one of the most striking findings is that rapamycin administration has been associated with a significant increase in subject lifespan, a result observed in multiple model organisms, including yeast [37], fruit flies [38], nematodes [39], and mice.[4046] In humans, oral rapamycin is absorbed rapidly with peak concentrations occurring within one to three hours depending on dosing protocol.[47, 48] In the bloodstream, the vast majority of rapamycin is distributed within red blood cells, and co-administration with a high fat meal can increase the oral bioavailability and AUC by up to 35% while decreasing the maximum blood concentration.[49, 50] In dogs, Larson et al
S.JungY.ReddyP
It works by mimicking the effects of human growth hormone (HGH) in the body, stimulating fat breakdown without affecting muscle mass
